| 标题 |
LBA44 Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O/ENGOT-ov46/GOG-3025 LBA44度伐鲁单抗+紫杉醇/卡铂+贝伐单抗随后度伐鲁单抗、贝伐单抗+奥拉帕尼维持治疗新诊断的非tBRCA突变晚期卵巢癌患者:DUO-O/ENGOT-ov46/GOG-3025的最终总生存期
|
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:C. Aghajanian; F. Trillsch; S. Nishio; A. Reuss; J-Y. Lee; et al 出版日期:2025-11-20 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |